Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA faces another QHC complaint

This article was originally published in The Tan Sheet

Executive Summary

Tea for Health marketer Fleminger Inc. challenges FDA's policy on qualified health claims for dietary supplements. The 1complaint filed June 1 in U.S. District Court for the District of Connecticut alleges the agency violated Fleminger's First Amendment rights by prohibiting truthful statements in its QHC regarding green tea and incidence of breast and prostate cancers. The complaint comes after a ruling in a separate case found FDA's 2009 decision to deny proposed QHCs linking selenium to reduced risk of site-specific cancers failed the First Amendment standard established in the 1999 Pearson v. Shalala decision (2"The Tan Sheet" June 7, 2010). According to Fleminger's lawsuit, FDA required the firm to use the QHC language the agency wrote, risk enforcement action if it used its own language, or make no claim at all. The Trumbull, Conn., firm argues FDA failed to apply the "least restrictive means of preventing any alleged deception of consumers." FDA denied Fleminger's QHC application in 2007, denied a petition for administrative review in 2008 and issued a February 2010 warning letter to the firm (3"The Tan Sheet" March 8, 2010)

You may also be interested in...

Selenium Claim Ruling Forces FDA's Hand, May Clear Path For More QHCs

A court decision obligating FDA to reconsider a slate of qualified health claims for selenium could compel the agency to allow more QHCs for dietary supplements

FDA's Flurry Of Food Claim Warnings Sends Bold Enforcement Message

A spate of FDA warning letters detailing labeling violations and an open letter from Commissioner Margaret Hamburg largely quash any hopes the food industry might have had for regulatory latitude to make aggressive health claims

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts